<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287091</url>
  </required_header>
  <id_info>
    <org_study_id>PIM4930g</org_study_id>
    <nct_id>NCT01287091</nct_id>
  </id_info>
  <brief_title>A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet</brief_title>
  <official_title>An Open-Label, 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This will be a single-center, open-label, 3 part study. The study is designed to determine
      the relative bioavailability of GDC-0980 capsule and tablet formulations under fasting
      conditions, the effects of a high-fat (fed) meal on the pharmacokinetics of the GDC-0980
      tablet, and the effects of rabeprazole on the pharmacokinetics of the GDC-0980 tablet in the
      presence or absence of a high-fat meal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>Up to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration</measure>
    <time_frame>Up to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma half-life</measure>
    <time_frame>Up to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral clearance</measure>
    <time_frame>Up to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>Up to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum plasma concentration</measure>
    <time_frame>Up to day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to day 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature of adverse events</measure>
    <time_frame>Up to day 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Up to day 68</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral tablet dose</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral capsule dose</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral tablet dose in fed state</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral repeating dose in fasting state</description>
    <arm_group_label>Part 3: Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral repeating dose in fed state</description>
    <arm_group_label>Part 3: Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral tablet in a fasting state</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>Part 3: Group A</arm_group_label>
    <arm_group_label>Part 3: Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Nonsmoking with a body mass index of 18 to 32 kg/m2

          -  Medically healthy as determined by the absence of clinically significant findings in
             the physical examination, medical history, vital sign measurements, clinical
             laboratory tests, or 12-lead electrocardiograms (ECGs)

          -  Nonchildbearing potential, defined as either postmenopausal and without recent history
             of menorrhea or surgically sterile

        Exclusion Criteria

          -  History or clinical manifestations of significant metabolic, hepatic, renal,
             hematological, pulmonary, cardiovascular, endocrine, gastrointestinal, urological,
             neurological, or psychiatric disorders, or cancer

          -  History of inflammatory arthritis

          -  History of symptomatic hypotension

          -  History of severe physical injury, direct impact trauma, or neurological trauma within
             6 months prior to study start

          -  History of seizure disorders

          -  History of bipolar or major depressive disorder

          -  History of stomach or intestinal surgery or resection that could potentially alter
             absorption and/or excretion of orally administered drugs with the exception of
             appendectomy, hernia repair, and cholecystectomy, which are allowed

          -  History or presence of an abnormal ECG

          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias

          -  Abnormality on the chest x-ray at Screening

          -  History of alcoholism, drug abuse, or drug addiction

          -  Used any nicotine-containing or nicotine-replacement products within 6 months prior to
             study start

          -  Participated in any other investigational drug study in which receipt of an
             investigational study drug occurred within 1 month or 5 half-lives prior to study
             start

          -  Used any prescription medications/products including monoamine oxidase inhibitors,
             thioridazine, pimozide, or antidepressants within 1 month (2 weeks for antibiotics)
             prior to study start, with the exception of hormone-replacement therapy or 2 weeks'
             use of narcotics for pain

          -  Received any vaccination or immunization within 1 month prior to study start

          -  Used PPIs or histamine H2-receptor antagonists within 1 month prior to study start

          -  Hypersensitivity to rabeprazole, or any of its components, or to derived products of
             benzimidazoles (for Part 3 only)

          -  Poor peripheral venous access

          -  Received blood products within 2 months prior to study start

          -  Positive urine drug or alcohol screen

          -  Positive screen for hepatitis B surface antigen, hepatitis C virus, or human
             immunodeficiency virus types 1 and 2

          -  Unable to consume a high-fat meal (for Parts 2 and 3 only)

          -  Acute or chronic condition that would limit the subject's ability to complete or
             participate in this clinical study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Holden, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

